Cancer prevention trials and primary care physicians: Factors associated with recommending trial enrollment

被引:10
作者
Battaglia, TA
Ash, A
Prout, MN
Freund, KM
机构
[1] Boston Univ, Sch Med, Womens Hlth Unit, Sect Gen Internal Med,Evans Dept Med, Boston, MA 02118 USA
[2] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA
[3] Boston Univ, Sch Med, Womens Hlth Interdisciplinary Res Ctr, Boston, MA 02118 USA
来源
CANCER DETECTION AND PREVENTION | 2006年 / 30卷 / 01期
关键词
breast neoplasms; chemoprevention; clinical trials; decision making; experimental design; high-risk patients; patient-provider relationship; prevention trials; primary care providers; primary prevention; regional variability; response rate; tamoxifen; trial enrolment;
D O I
10.1016/j.cdp.2005.09.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To explore the willingness of primary care providers (PCPs) to encourage enrollment of patients into cancer prevention trials. Methods: A self-administered survey was mailed to a random sample of PCPs in three geographic regions. Physicians were asked questions about their knowledge and attitudes towards cancer prevention trials. We presented a clinical vignette of a woman at high risk for breast cancer and asked if they would encourage her enrollment into a breast cancer chemoprevention trial (yes/no). Each survey included one of 16 possible clinical vignettes where patient characteristics (age, race socioeconomic status, physical mobility and comorbidity) varied dichotomously. Bivariate analyses and logistic models were used to examine the independent effects of patient and physician characteristics on physician decisions. Results: Two hundred and sixty-six surveys (50% response) were analyzed. The mean age of respondents was 48; 54% were White, 35% Asian and 5% Black. By design physicians were evenly distributed by gender, specialty and geographic location. Overall, 53% would encourage enrollment into a breast cancer chernoprevention trial. Significant predictors of a recommendation to enroll were: geographic location in California or Georgia, younger vignette patient and anticipating an increase in patient trust after recommending enrollment. Conclusion: PCPs are less likely to encourage elderly patients to enroll into cancer chemoprevention trials. Decisions differ based on a trust in the patient-provider relationship. To achieve successful enrollment, trial investigators must geographic location and perceived it continue to educate PCPs and ensure a strong PCP-patient relationship is maintained. (c) 2005 International Society for Preventive Oncology. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:34 / 37
页数:4
相关论文
共 21 条
[1]   Response rates to mail surveys published in medical journals [J].
Asch, DA ;
Jedrziewski, MK ;
Christakis, NA .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1997, 50 (10) :1129-1136
[2]   ONCOLOGISTS RELUCTANCE TO ACCRUE PATIENTS ONTO CLINICAL-TRIALS - AN ILLINOIS CANCER CENTER STUDY [J].
BENSON, AB ;
PREGLER, JP ;
BEAN, JA ;
RADEMAKER, AW ;
ESHLER, B ;
ANDERSON, K .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (11) :2067-2075
[3]   Chemoprevention of breast cancer: Recommendations and rationale [J].
Berg, AO ;
Allan, JD ;
Frame, P ;
Homer, CJ ;
Johnson, MS ;
Klein, JD ;
Lieu, TA ;
Mulrow, CD ;
Orleans, TC ;
Peipert, JF ;
Pender, NJ ;
Siu, AL ;
Teutsch, SM ;
Westhoff, C ;
Woolf, SH .
ANNALS OF INTERNAL MEDICINE, 2002, 137 (01) :56-58
[4]  
Cochran W.G. G.M. Cox., 1957, Experimental Design
[5]   PRESERVING THE PHYSICIAN-PATIENT RELATIONSHIP IN THE ERA OF MANAGED CARE [J].
EMANUEL, EJ ;
DUBLER, NN .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (04) :323-329
[6]   GEOGRAPHIC-VARIATION IN THE TREATMENT OF LOCALIZED BREAST-CANCER [J].
FARROW, DC ;
HUNT, WC ;
SAMET, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (17) :1097-1101
[7]   Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study [J].
Fisher, B ;
Costantino, JP ;
Wickerham, DL ;
Redmond, CK ;
Kavanah, M ;
Cronin, WM ;
Vogel, V ;
Robidoux, A ;
Dimitrov, N ;
Atkins, J ;
Daly, M ;
Wieand, S ;
Tan-Chiu, E ;
Ford, L ;
Wolmark, N .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) :1371-1388
[8]  
Frayne SM, 2001, J NATL MED ASSOC, V93, P450
[9]  
GLASS RM, 1996, JAMA-J AM MED ASSOC, V275, P1693
[10]   Underrepresentation of patients 65 years of age or older in cancer-treatment trials. [J].
Hutchins, LF ;
Unger, JM ;
Crowley, JJ ;
Coltman, CA ;
Albain, KS .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (27) :2061-2067